Cocoa futures gained ground on Monday, reversing recent losses, as data showing reduced deliveries to ports in top-producer Ivory Coast triggered short-covering. The uptick comes despite a backdrop of ample global stocks and persistent demand weakness in key markets.
U.S. stocks advanced cautiously Monday as investors braced for a wave of corporate earnings reports, while crude oil prices tumbled sharply. The focus remains on key tech results and evolving geopolitical developments affecting global trade and energy markets.
U.S. stocks advanced Monday, buoyed by a surprisingly strong manufacturing report that overshadowed lingering concerns over a partial government shutdown and weak economic data from China. The S&P 500 and Dow Jones Industrial Average both closed higher, led by a rebound in semiconductor and AI-related shares.
U.S. equities edged higher Monday, buoyed by a rebound in semiconductor and AI infrastructure stocks, alongside a surge in rare earth companies following a new strategic initiative. Gains were tempered by falling energy shares, cryptocurrency volatility, and ongoing concerns over a partial government shutdown.
A powerful but uncommon shift in market leadership is underway as small-caps, energy, and value stocks drive gains. While a sign of health, historical parallels to similar 'breadth' events often coincided with economic stress.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Pzena Investment Management's Focused Value Strategy lagged behind its benchmark in Q4 2025, with semiconductor firm Skyworks Solutions cited as a key detractor. The fund's commentary highlights the challenges for value investing in a market dominated by AI and mega-cap stocks.
Investment firm Curreen Capital posted strong 2025 results, crediting its focus on undervalued 'ugly duckling' stocks. The fund's latest letter spotlights VF Corporation (VFC), the embattled owner of Vans and The North Face, as a potential turnaround play despite its shares falling over 20% in the past year.
After a punishing multi-year slump, materials stocks are showing signs of life in 2026. Dow and LyondellBasell, offering yields of 5% and 10.9% respectively, present a high-risk, high-reward proposition for income investors betting on a sector recovery.
As the TSX rides a wave of broad-based earnings optimism, a closer look reveals smaller companies, often miscategorized as 'penny stocks', that combine financial resilience with clear growth trajectories. We examine three such firms with market caps up to CA$700 million.
A combination of moderating inflation and resilient corporate earnings is setting the stage for sustained stability in stock markets, with the recent rally now encompassing small-caps, value stocks, and multiple sectors.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
Analyst Joe Laetsch raises HF Sinclair's price target, highlighting favorable crude differentials and a recent $38 million acquisition aimed at expanding its lubricants business, as the refiner lands on a list of top low-risk dividend stocks.
Amid a mixed market landscape, corporate insiders are placing significant bets on select small-cap stocks. We analyze three companies where recent insider buying and strategic moves signal potential value, despite broader economic headwinds.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
After a punishing year for many restaurant stocks, a seismic shift is underway. As inflation-weary diners become more selective, value and experience are trumping category labels, driving a surprising resurgence in casual dining while challenging the fast-casual model.
